Mark Kaye, the chief financial officer, said the company took a "very disciplined approach between competitiveness and underwriting." ...

Mark Kaye, the chief financial officer, said the company took a "very disciplined approach between competitiveness and underwriting." ...

After a dip in the wake of the release of UnitedHealth Group's Q4 2024 earnings figures, shares in the company and other ...

We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click here to read more.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a ...

Shares of Elevance Health Inc. ELV slipped 1.42% to $405.40 Tuesday, on what proved to be an all-around great trading session ...

In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...

Shaun Grannis Dr. Shaun Grannis, vice president of data and analytics at the Indianapolis-based Regenstrief Institute, told IBJ technology-driven mental health tools hold the potential to help but ...

Gail Boudreaux; President, Chief Executive Officer, Director; Elevance Health Inc Mark Kaye; Chief Financial Officer, Executive Vice President; Elevance Health Inc Felicia Norwood; Executive Vice ...

Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.

Elevance Health Inc. closed 27.50% below its 52-week high of $567.26, which the company achieved on September 3rd.